Comparison of VA dysfunction risk at 1 year after VA creation in AVG patients who received different doses of antiplatelet drugs.</p
<p>Baseline characteristics and outcomes of anticoagulant users compared between upper and lower GI ...
BACKGROUND Randomized controlled trials comparing short- (= 1 year) dual antiplatelet therapy (DAPT)...
<p>Comparison of characteristics of patients who developed VTE during the follow-up to those with no...
Comparison of VA dysfunction risk at 1 year after VA creation in AVF patients who received different...
Comparison of VA dysfunction risk at 1 year after VA creation in AVF and AVG patients who used diffe...
<p>Dash lines represent individual patient measurements, and darker solid lines represent predicted ...
Risk of recurrent VTE, major bleeding, and CRNM bleeding for apixaban vs. warfarin among VTE patient...
Risk of recurrent VTE, major bleeding, and CRNM bleeding for apixaban vs. warfarin among VTE patient...
Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major bleeding during ...
<p>Drugs with expected long-term treatments (panels B and D) generally presented with longer RTTO th...
Descriptive pre- and post-IPTW baseline characteristics among VTE patients at a high risk of bleedin...
<p>Comparison of solicited adverse events following the first and second doses of vaccine (n = 44) a...
<p>Comparison of the risk of hospitalized infection during the first year of follow-up between treat...
BACKGROUND: There is general agreement that the optimal duration of dual antiplatelet therapy (DAPT)...
<p>Hazard rate ratios of ischemic stroke and all-cause death after 1-year follow-up, stratified by a...
<p>Baseline characteristics and outcomes of anticoagulant users compared between upper and lower GI ...
BACKGROUND Randomized controlled trials comparing short- (= 1 year) dual antiplatelet therapy (DAPT)...
<p>Comparison of characteristics of patients who developed VTE during the follow-up to those with no...
Comparison of VA dysfunction risk at 1 year after VA creation in AVF patients who received different...
Comparison of VA dysfunction risk at 1 year after VA creation in AVF and AVG patients who used diffe...
<p>Dash lines represent individual patient measurements, and darker solid lines represent predicted ...
Risk of recurrent VTE, major bleeding, and CRNM bleeding for apixaban vs. warfarin among VTE patient...
Risk of recurrent VTE, major bleeding, and CRNM bleeding for apixaban vs. warfarin among VTE patient...
Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major bleeding during ...
<p>Drugs with expected long-term treatments (panels B and D) generally presented with longer RTTO th...
Descriptive pre- and post-IPTW baseline characteristics among VTE patients at a high risk of bleedin...
<p>Comparison of solicited adverse events following the first and second doses of vaccine (n = 44) a...
<p>Comparison of the risk of hospitalized infection during the first year of follow-up between treat...
BACKGROUND: There is general agreement that the optimal duration of dual antiplatelet therapy (DAPT)...
<p>Hazard rate ratios of ischemic stroke and all-cause death after 1-year follow-up, stratified by a...
<p>Baseline characteristics and outcomes of anticoagulant users compared between upper and lower GI ...
BACKGROUND Randomized controlled trials comparing short- (= 1 year) dual antiplatelet therapy (DAPT)...
<p>Comparison of characteristics of patients who developed VTE during the follow-up to those with no...
DOI
Add to ORKG